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Batf3-Dependent CD11blow/2 Peripheral Dendritic Cells
Are GM-CSF-Independent and Are Not Required for Th
Cell Priming after Subcutaneous Immunization
1

1,2¤

Brian T. Edelson1, Tara R. Bradstreet1, Wumesh KC , Kai Hildner , Jeremy W. Herzog 1, Julia Sim3,
John H. Russell3, Theresa L. Murphy1, Emil R. Unanue1, Kenneth M. Murphy1,2*
1 Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri, United States of America, 2 Howard Hughes Medical Institute,
Washington University School of Medicine, St. Louis, Missouri, United States of America, 3 Department of Developmental Biology, Washington University School of
Medicine, St. Louis, Missouri, United States of America

Abstract
Dendritic cells (DCs) subsets differ in precursor cell of origin, functional properties, requirements for growth factors, and
dependence on transcription factors. Lymphoid-tissue resident CD8a+ conventional DCs (cDCs) and CD11blow/2CD103+
non-lymphoid DCs are developmentally related, each being dependent on FMS-like tyrosine kinase 3 ligand (Flt3L), and
requiring the transcription factors Batf3, Irf8, and Id2 for development. It was recently suggested that granulocyte/
macrophage colony stimulating factor (GM-CSF) was required for the development of dermal CD11blow/2Langerin+CD103+
DCs, and that this dermal DC subset was required for priming autoreactive T cells in experimental autoimmune encephalitis
(EAE). Here, we compared development of peripheral tissue DCs and susceptibility to EAE in GM-CSF receptor deficient
(Csf2rb2/2) and Batf32/2 mice. We find that Batf3-dependent dermal CD11blow/2Langerin+ DCs do develop in Csf2rb2/2
mice, but that they express reduced, but not absent, levels of CD103. Further, Batf32/2 mice lacking all peripheral CD11blow/2
DCs show robust Th cell priming after subcutaneous immunization and are susceptible to EAE. Our results suggest that
defective T effector priming and resistance to EAE exhibited by Csf2rb2/2 mice does not result from the absence of dermal
CD11blow/2Langerin+CD103+ DCs.
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reduced EAE severity but did not eliminate disease, and non-IL-17
and non-IFN-c pathways have been implicated [8–10]. IL-23, but
not IL-6 or TGF-b, was found to be critical for regulating the
pathogenicitiy of Th17 cells [11,12]. GM-CSF derived from T
cells, but not other CNS-resident or peripheral immune cells, was
required for development of EAE [5], and acted during the
effector phase to augment pathogenicity of Th17 cells [6,7]. IL-23
induced Th17 cells to increase production of GM-CSF, which
further enhanced IL-23 production by antigen-presenting cells [6].
RORct was shown to induce GM-CSF, which acted on infiltrating
myeloid cells entering the CNS, rather than resident microglia,
during the development of EAE [7]. These studies suggest a model
of EAE in which pathogenic T cells secrete GM-CSF that activates
myeloid cells infiltrating the CNS to produce pathogenic lesions
and further amplifies IL-23 production by DCs [13].
A recent report has suggested that the role for GM-CSF in EAE
was based on its requirement for the development of dermal
CD11blow/2Langerin+CD103+ DCs [14]. Dermal CD11blow/2
Langerin+CD103+ DCs represent one anatomic subtype of
peripheral tissue CD11blow/2CD103+ DCs, all of which share with

Introduction
GM-CSF regulates the development and activity of several
myeloid cell types and influences both the initiation and
maintenance of adaptive immune responses [1]. Mice lacking
GM-CSF or its receptor show decreased antigen specific T cell
priming against the encephalitogenic peptide of myelin oligodendrocyte glycoprotein (MOG35–55) and are resistant to EAE [2].
Beyond this role in priming adaptive immune responses, GM-CSF
acts to sustain ongoing effector responses, both in EAE initiated by
MOG35–55 peptide [2] and in collagen-induced arthritis [3].
Similarly, in a murine model of autoimmune myocarditis, GMCSF acts during priming of Th17 responses by promoting IL-6
and IL-23 production from DCs and during ongoing autoimmune
responses by promoting survival of autoreactive CD4+ T cells [4].
Several recent studies indicate that it is GM-CSF rather than
IL-17 that is the primary Th17-derived cytokine responsible for
the development of EAE [5–7]. Initially, it was thought that IL-17
production would explain why Th17 cells and RORct were
required for EAE. However, in vivo neutralization of IL-17 only
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lymphoid tissue CD8a+ cDCs developmental dependence on Batf3,
Irf8, and Id2 [15,16]. CD8a+ cDCs are cross-presenting DCs,
characterized by consistent expression of DEC205, and variable
expression of CD103 which can be regulated by GM-CSF, IL-3,
and TGF-b1 [17–19]. Mice lacking GM-CSF or the GM-CSF
receptor
were reported to lack dermal CD11blow/2Langer+
+
in CD103 DCs in the skin and peripheral lymph nodes under
steady state and inflammatory conditions, and were resistant to EAE
[14]. In addition, radiation chimeras expressing the human
diphtheria toxin receptor (DTR) controlled by the Langerin
promoter [20] and depleted of peripheral CD11blow/2Langer+
in CD103+ DCs were resistant to EAE and had reduced priming of
MOG35–55 -specific T cells [14]. This study concluded that GMCSF was required for the initiation of EAE because it was required
for the development of dermal CD11blow/2Langerin+CD103+
DCs, which were required to prime pathogenic T cells [14].
To test whether loss of GM-CSF receptor protects from EAE by
eliminating dermal CD11blow/2Langerin+CD103+ DCs, we asked
if Batf32/2 mice, which also lack this DC subset, are also protected
from EAE. We find that Batf32/2 mice develop EAE after
immunization and have increased numbers of MOG35–55 peptidespecific T cells, excluding a requirement for either peripheral
CD11blow/2CD103+ DCs or lymphoid tissue-resident CD8a+
DCs in EAE development. Direct comparison of Batf32/2 and
GM-CSF receptor deficient mice revealed that GM-CSF signaling
was not required for the development of dermal CD11blow/2
Langerin+CD103+ DCs, but rather regulated the expression level
of CD103 on all peripheral DCs.

Results
Batf32/2 mice develop EAE following MOG immunization
To compare Batf32/2 mice with mice lacking the GM-CSF
receptor (Csf2rb2/2) on the same genetic background, we
backcrossed Batf32/2 mice onto the C57BL/6 background for
10 generations. Csf2rb2/2 mice lack the common b-chain for
signaling through receptors for GM-CSF, IL-5, and IL-3.
However, mice have a second b-chain, Csf2rb2, which selectively
pairs with the IL-3 receptor a-chain. Thus, Csf2rb2/2 mice lose
responsiveness to GM-CSF and IL-5, but not to IL-3 [21,22]. Wild
type (C57BL/6), Batf32/2, and Csf2rb2/2 mice were subcutaneously immunized with MOG35–55 peptide as previously described
and followed for clinical disease [14]. Csf2rb2/2 mice remained
disease free as reported [14], but Batf32/2 mice developed EAE
with the same severity and kinetics as wild type C57BL/6 mice
(Fig. 1A).
In draining lymph nodes, examination by ELISPOT assay
showed that immunized Batf32/2 mice had an increased
frequency of MOG35–55-specific T cells producing IL-17 and
IFN-c (Fig. 1B), while Csf2rb2/2 mice had a significantly reduced
frequency of such cells, as previously reported [14]. Thus, Batf32/2
mice, which lack all peripheral CD11blow/2CD103+ DCs [16], are
able to prime pathogenic CD4+ T cells, and remain susceptible to
EAE. These findings would disagree with the interpretation that
resistance to EAE in Csf2rb2/2 mice results from the absence of
dermal CD11blow/2Langerin+CD103+ DCs as was recently
suggested [14].

Figure 1. Batf32/2 mice are susceptible to EAE. (A) Clinical course
of EAE in C57BL/6 mice, Batf32/2 mice (C57BL/6 background), and
Csf2rb2/2 mice. Data are combined from two experiments (n = 10 mice
per group). Points represent the mean clinical score. For clarity, error
bars are not displayed. (B) ELISPOT assays on popliteal lymph node cells
at day 7 following footpad immunization (MOG35–55 peptide in CFA)
and restimulation with MOG35–55 peptide. Data are from one of two
similar experiments (n = 3 per group). Mean 6 SEM, p values by
unpaired student’s t test.
doi:10.1371/journal.pone.0025660.g001

C57BL/6, Batf32/2, and Csf2rb2/2 mice for expression of
markers that distinguish between Batf3-dependent and Batf3independent DC subsets (Fig. 2A).
In skin draining lymph nodes (SDLNs), migratory DCs are
evident as DEC205+CD8a2 cells, which can be divided into at
least three subsets based on CD11b, Langerin, and CD103
expression [23–25]. C57BL/6, Batf32/2, and Csf2rb2/2 mice
each contained normal populations of dermal Langerin2 DCs and
Langerhans cells of the epidermis (CD11b+Langerin+CD1032EpCAMhigh) (Fig. 2A). However, differences were evident in the
dermal CD11blow/2Langerin+CD103+ DCs between these strains.
C57BL/6 mice contained the normal population of dermal
CD11blow/2Langerin+CD103+EpCAMmid DCs, which were missing in Batf32/2 mice [16]. Notably, Csf2rb2/2 mice retained this
population of dermal DCs, but in this strain of mice, these DCs
expressed slightly lower levels of CD103 relative to C57BL/6
mice. CD24 can also been used to distinguish between populations
of dermal DCs [26], and similarly C57BL/6 mice contained a
population of dermal Langerin+CD24+EpCAMmid DCs that were
completely missing in Batf32/2 mice, but which were present in
Csf2rb2/2 mice (Fig. 2B). Csf2rb2/2 mice showed reduced total

Csf2rb2/2 mice retain development of Batf3-dependent
dermal CD11blow/2Langerin+ DCs
GM-CSF was recently reported to directly regulate CD103
expression on splenic CD8a+ DCs [17–19], so conceivably
Csf2rb2/2 mice might retain dermal CD11blow/2Langerin+ DCs
that simply lack CD103. To test this, we examined DCs from
PLoS ONE | www.plosone.org
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Figure 2. Batf3-dependent dermal CD11blow/2Langerin+ DCs develop in Csf2rb2/2 mice, but lack expression of CD103. (A) FACS
analysis of SDLN (inguinal) DCs from C57BL/6, Batf32/2 (C57BL/6 background), and Csf2rb2/2 mice. Left plots are gated on CD11chigh cells. The
second column is gated on migratory (DEC205+CD8a2) DCs. The third, fourth, and fifth columns are gated on Langerin+ migratory DCs. Numbers
represent the percentage of cells within the indicated gates. MFI are shown for the indicated gates. Data are representative of eight to ten individual
inguinal lymph nodes from four to five mice per genotype over two experiments. (B) FACS analysis of SDLN (inguinal) DCs from C57BL/6, Batf32/2,
and Csf2rb2/2 mice. Left plots are gated on CD11chigh cells. Middle plots are gated on migratory (DEC205+CD8a2) DCs. Right plots are gated on all
Langerin+ migratory DCs, independent of expression of CD11b. Numbers represent the percentage of cells within the indicated gates. Data are
representative of inguinal lymph nodes from at least five mice per genotype for all stains except CD24, which has been performed on one mouse per
genotype. (C) Absolute cell numbers per individual inguinal lymph nodes calculated from the FACS analysis in (A). Langerhans cells were gated as
Langerin+CD11b+EpCAMhigh DCs, and dermal Langerin+ DCs were gated as Langerin+CD11blow/2EpCAMmid DCs. Horizontal bars represent the
geometric mean; p values by unpaired student’s t test. (D) Clinical course of EAE in 129S6/SvEv mice and Batf32/2 mice (129S6/SvEv background).
Data are from one of three similar experiments (n = 5 mice per group). Points represent the mean clinical score. For clarity, error bars are not
displayed.
doi:10.1371/journal.pone.0025660.g002

lymph node cellularity and a reduced number of overall lymph
node DCs, but normal numbers of Langerhans cells and dermal
CD11blow/2Langerin+ DCs (Fig. 2C). Batf32/2 mice showed a
selective ,100-fold reduction in the number of dermal CD11blow/2
Langerin+ DCs. These results indicate that Csf2rb2/2 mice do
contain dermal CD11blow/2Langerin+ DCs, but that in the absence
of GM-CSF signaling, CD103 expression is reduced.

As with C57BL/6 Batf32/2 mice, Batf32/2 mice on the129S6/
SvEv background were equally as susceptible to EAE as wild type
controls. Thus, loss of dermal CD11blow/2CD103+ DCs could not
have explained the resistance to EAE that was observed in
Csf2rb2/2 mice.

C57BL/6 Batf32/2 mice contain CD8a+ cDCs in SDLNs but
not spleen

We next compared C57BL/6, Batf32/2, and Csf2rb2/2 mice for
the presence of DC subsets in peripheral tissues, specifically the lung
and kidney. In the lung, DCs exist as two populations, characterized
as Batf3-dependent CD11blow/2LangerinmidCD103+ DCs and
Batf3-independent CD11b+Langerin2CD1032 DCs. Lungs from
Batf32/2 mice completely lacked CD11blow/2LangerinmidCD103+
DCs (Figure 3A) as expected [16]. Importantly, lungs from
Csf2rb2/2 mice retained a normal population of pulmonary
CD11blow/2 DCs, which expressed reduced levels of CD103 and
undetectable levels of Langerin (Fig. 3A). Csf2rb2/2 mice develop
alveolar proteinosis due to defective surfactant handling by lung
macrophages in the absence of GM-CSF signaling [21]. Conceivably, this inflammatory process could have influenced CD103
expression by CD11blow/2 lung DCs. To test this, we examined
CD103 expression by DCs of the kidney, since this organ shows no
pathology in Csf2rb2/2 mice. Again, while Batf32/2 mice completely
lacked CD11blow/2CD103+ kidney DCs, Csf2rb2/2 mice had
normal numbers of CD11blow/2 kidney DCs, but which expressed
moderately reduced levels of CD103 (Fig. 3B). In summary, it
appears that Csf2rb2/2 mice retain normal development of
peripheral tissue CD11blow/2 which express reduced levels of
CD103.

Csf2rb2/2 mice retain Batf3-dependent CD11blow/2
peripheral tissue DCs with reduced CD103 expression

In analyzing SDLNs of C57BL/6 Batf32/2 mice, we noticed an
unexpected population of DEC205+CD8a+ cDCs that were
eliminated in the spleen and SDLNs of 129S6/SvEv Batf32/2
mice [16,27] (Fig. 2A, 2C). Therefore, we directly compared DCs
from SDLNs of Batf32/2 mice on both genetic backgrounds (Fig.
S1A). C57BL/6 Batf32/2 mice lacked dermal CD11blow/2CD103+
DCs (Fig. S1A) but had a persistence of DEC205+CD8a+ cDCs in
peripheral lymph nodes (Fig. S1A, S1B). In spleens, Batf32/2 mice
showed a significant decrease in DEC205+CD8a+ cDCs on both
C57BL/6 and 129S6/SvEv backgrounds compared to controls (Fig.
S1C, S1D). On the 129S6/SvEv background, DEC205+CD8a+
cDCs were reduced from 4.8% of splenic cDCs in control mice to
only 0.11% of splenic cDCs in Batf32/2 mice. On the C57BL/6
background, DEC205+CD8a+ cDCs were reduced from 14% of
splenic cDCs in control mice to only 2.5% of splenic cDCs in
Batf32/2 mice (Fig. S1C, S1D). Thus, for splenic cDCs, Batf3 is
non-redundant in the development of DEC205+CD8a+ cDCs.
While loss of Batf3 does not eliminate the population of
DEC205+CD8a+ cDCs in SDLNs, these cells did not express
CD103 normally (Fig. S1E). 9% of the DEC205+CD8a+ cDCs in
SDLNs of control mice expressed CD103, while only 1.8%
expressed CD103 from Batf32/2 mice. Notably, CD103 expres
sion was also reduced on this population from SDLNs of Csf2rb2/2
mice. Conceivably, the persistence of DEC205+CD8a+ cDCs in
SDLNs on the C57BL/6 background could result from genetic
polymorphisms that impact the redundancy of Batf3 in the
development of these cells. Alternately, variable inflammation
between strains could be involved, since infection with Toxoplasma
gondii can regulate the size of splenic CD11blow/2CD103+ DC
populations [28].

Basal CD103 expression by CD8a+-equivalent cDCs
requires Batf3 but not GM-CSF signaling
While CD103 has been used as a marker for the dermal
CD11blow/2Langerin+ DC lineage [14], recent work shows that
CD103 expression can be dynamically regulated by cytokines
[17,18]. Therefore, we wished to re-examine the relationships
between CD103 expression, Batf3, and GM-CSF signaling. We
selected the Flt3L-induced DC differentiation from bone marrow
cultures for this purpose since it has allowed the analysis of CD103
expression as dependent on both Batf3 and GM-CSF [17,18]
(Fig. 4).
Previously, CD24high SIRPalow DCs were considered an
‘‘equivalent’’ of CD8a+ cDCs in Flt3L-treated bone marrow
cultures [30], despite the fact that only a subpopulation of these
cells express CD103 (Fig. 4). The CD103+ fraction of CD24high
SIRPalow DCs was more potent than the CD1032 fraction for
cross-presentation [17], suggesting a correlation between CD103
expression and CD8a+ cDC function. We find that addition of

129S6/SvEv Batf32/2 are susceptible to EAE
Conceivably, persistence of DEC205+CD8a+ cDCs in SDLNs
of C57BL/6 Batf32/2 mice was the basis for their susceptibility to
EAE, based on potentially overlapping functions for
DEC205+CD8a+ cDCs and dermal CD11blow/2CD103+ DCs
[29]. To test this, we examined Batf32/2 mice on the 129S6/SvEv
background, which lack both DEC205+CD8a+ and dermal
CD11blow/2CD103+ DCs in both spleen and SDLNs (Fig. 2D).
PLoS ONE | www.plosone.org
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Figure 3. GM-CSF controls the level of CD103 expression on Batf3-dependent CD11blow/2 peripheral DCs. (A) FACS analysis of lung DCs
from C57BL/6, Batf32/2 (C57BL/6 background), and Csf2rb2/2 mice. Left plots are gated on live, single cells. The second column of plots is gated on
CD11c+CD45.2+ cells, consisting of a mixture of lung macrophages and DCs. Note that in Csf2rb2/2 mice, lung macrophages lack CD11c expression
[38], and therefore this gate includes only DCs. The third and fourth columns of plots are gated on I-Abhigh autofluorescencelow DCs. Numbers
represent the percentage of cells within the indicated gates. Data are representative of six individual lungs from three mice per genotype over two
experiments. (B) FACS analysis of kidney DCs from C57BL/6, Batf32/2 (C57BL/6 background), and Csf2rb2/2 mice. Left plots are gated on live, single
cells. The second column of plots is gated on CD11chighCD45.2+ cells, consisting of DCs. The third column of plots is gated on CD11chighI-Ab+ DCs.
Numbers represent the percentage of cells within the indicated gates. Data are representative of six individual kidneys from three mice per genotype
over two experiments.
doi:10.1371/journal.pone.0025660.g003

examined in the previous studies. Notably, a separate report has
suggested that GM-CSF signaling is required for the development
of small intestinal lamina propria CD11b+CD103+ DCs [31],
although their data could be reinterpreted as simply representing
reduced CD103 expression by these DCs. In that report, Csf2rb2/2
mice had half as many lamina propria CD11b+CD103+ DCs as wild
type mice, but 1.7-fold more CD11b+CD1032 DCs than wild type
mice, consistent with a reduction of CD103 expression as an
explanation for the ‘‘missing’’ subset.
King et al. also found decreased T cell priming to subcutaneous
immunization with MOG35–55 peptide and partial EAE resistance
after in vivo depletion of peripheral Langerin+CD103+ DCs using
radiation chimeras reconstituted with bone marrow from transgenic
mice expressing DTR under the control of the Langerin promoter
[20]. The use of radiation chimeras allowed the selective depletion
of dermal CD11blow/2Langerin+ DCs, avoiding depletion of
epidermal CD11b+Langerin+ Langerhans cells, because the latter
are radiation-resistant, and were therefore of host origin and did not
express the DTR. Our results indicate that Csf2rb2/2 mice are not
deficient in dermal CD11blow/2Langerin+ DCs, but rather that
these cells have reduced CD103 expression. However, Batf32/2
mice lack this dermal DC subset, and yet are susceptible to EAE
induction and display increased, not decreased, T cell priming to
MOG35–55 peptide immunization. It is unclear why DTR-mediated
depletion of donor-derived, radiation-sensitive Langerin+ DCs
reduces priming and delays EAE, when genetic ablation of these
cells in Batf32/2 mice leaves priming and EAE intact. Their use of
DTR-mediated depletion involved irradiation of mice prior to
immunization, which may have had unintended consequences.
Furthermore, a study by Henri et al. has identified additional
dermal DC subsets [26], including one that is Langerin+ but
CD1032, although it’s Batf3-dependence was not characterized.
Conceivably, the depletion of this subset by diphtheria toxin
treatment could contribute to differences between our results and
those of King et al. Notably, DTR-mediated depletion reduced the
severity of EAE, but with a profound decrease only in MOG35–55specific IFN-c-secreting T cells, with minimal change in the number
of IL-17-secreting T cells. In contrast, MOG35–55-immunized
Csf2rb2/2 mice had profound reductions in antigen-specific IFNc-secreting and in IL-17-secreting T cells, suggesting that Csf2rb2/2
mice differ from mice in which Langerin+ DCs are depleted using
DTR.
Our results suggest that the absence of dermal CD11blow/2
Langerin+CD103+ DCs leads to augmented T cell priming of both
Th17 and Th1 responses. Igyártó et al. have recently shown that
skin infection of Batf32/2 mice with recombinant Candida albicans
led to reduced Th1 but increased Th17 responses compared to
control mice [32]. These authors demonstrated that dermal
Langerin+CD103+ DCs expressed IL-12, explaining their ability
to promote Th1 cell responses, and IL-27, a cytokine known to
inhibit Th17 cell responses [33,34]. While we found increased Th17
responses in Batf32/2 mice immunized with MOG35–55 and CFA,
we also observed increased Th1 responses compared to control

GM-CSF during day 7 through 9 of Flt3L culture induces CD103
expression on all CD24high SIRPalow DCs (Fig. 4), in agreement
with recent reports which showed that such GM-CSF-induced
cells exhibit robust cross-presentation [17,18]. However, while
addition of IL-3 and TGF-b1 to Flt3L cultures can both induce
expression of CD103, only IL-3 induced the capacity for crosspresentation [17], dissociating CD103 expression from crosspresentation. Likewise, we found that GM-CSF treatment induced
CD103 expression on all CD24highSIRPalow DCs, even in bone
marrow cultures from Batf32/2 mice (Fig. 4), which completely
lack CD103+ DCs in vivo [16], further dissociating CD103
expression from the properties of true CD8a+ cDC equivalents.
In agreement, a recent report found that GM-CSF-induced
CD103+CD24highSIRPalow Flt3L-derived DCs from Batf32/2
mice lacked the capacity for cross-presentation [18]. Finally,
Csf2rb2/2 bone marrow generated a subpopulation of
CD103+CD24highSIRPalow DCs, indicating development that is
independent of GM-CSF signaling, although whether these arise
from the actions of cytokines such as IL-3, or arise independently
of soluble factors present in the culture remains unknown. In
summary, these results indicate that CD103 expression can be
regulated by GM-CSF, independently of Batf3, and may not
represent a static marker of Batf3-dependent DC lineages.

Discussion
Our study makes two new observations. First, we show that
CD11blow/2 non-lymphoid DCs develop in the absence of GMCSF signaling. Second, we show that Batf3-dependent CD11blow/2
non-lymphoid DCs are not required for T effector cell priming or
clinical EAE after subcutaneous immunization. King et al. recently
concluded that mice deficient for GM-CSF or GM-CSF receptor
were resistant to EAE because they lacked dermal CD11blow/2
Langerin+CD103+ DCs, which they proposed were required for
priming effector CD4 T cells with MOG35–55 [14]. Dermal
CD11blow/2Langerin+CD103+ DCs are a conventional DC subset
that requires the transcription factor Batf3 for their development
[16]. Here, we directly compared Csf2rb2/2 with Batf32/2 mice for
their susceptibility to EAE and for their development of various DC
subsets using a broad panel of DC markers, including Langerin,
CD11b, EpCAM, CD24, and CD103. We confirm that the dermal
CD11blow/2Langerin+CD103+ DC subset is absent in Batf32/2
mice, but surprisingly find that Csf2rb2/2 mice harbor normal
numbers of this DC subset in SDLNs as a CD11blow/2
Langerin+EpCAMmidCD24high cell that expresses reduced, but
not absent, levels of CD103. Moreover, in other peripheral tissues,
Csf2rb2/2 mice have similar CD11blow/2CD103+ DCs that express
reduced, but not absent, levels of CD103.
Our data agree with recent reports that GM-CSF directly
regulates CD103 expression on Flt3L-derived CD8a+ equivalent
cDCs and splenic DEC205+CD8a+ cDCs [17–19]. Beyond this,
we show that GM-CSF also regulates levels of CD103 expression
on peripheral tissue-resident CD11blow/2 DCs, which were not
PLoS ONE | www.plosone.org
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Figure 4. GM-CSF induces CD103 expression on Flt3L-derived CD8a-equivalent DCs. FACS analysis of developing DCs in bone marrow
cells from C57BL/6, Batf32/2 (C57BL/6 background), and Csf2rb2/2 mice cultured with Flt3L for 9 days, with or without the addition of GM-CSF to the
culture on day 7. The left column is gated on live single cells, the second on CD11c+CD45RA2 cDCs, the third on I-Ab+ cDCs, and the fourth on
CD24highSirpalow cells. Numbers represent the percentage of cells within the indicated gates. Data are representative of bone marrow cells from two
mice per genotype over two experiments.
doi:10.1371/journal.pone.0025660.g004
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for signs of EAE and graded on a standard 0–5 scale as described
[37].

mice. Conceivably, the different Th1 responses between our study
and Igyártó et al. could arise from differences in the form of
immunization, relying on CFA versus fungal infection. Notably,
blood-derived inflammatory monocytes have been reported to serve
as a critical source of IL-12 after CFA-based subcutaneous
immunization [35]. While we observed between a 2 to 3-fold
higher frequency of IL-17-producing T cells in MOG35–55immunized Batf32/2 mice relative to controls, the clinical EAE
scores were similar between these groups. Conceivably, the
frequency of IL-17-producing T cells is unrelated to the severity
of EAE when Th17 cells are above some threshold frequency.
Alternatively, IL-17 itself may not be the limiting factor in
regulating the intensity of EAE, since GM-CSF also recently was
implicated as the major Th17-derived cytokine responsible for
driving pathogenic lesions in this model [5–7]. In fact, however, we
do observe a slightly more rapid onset of EAE in Batf32/2 mice,
which was more pronounced in the 129S6/SvEv genetic background (Fig. 2D), which could relate to increased Th17 development.
If a lack of peripheral CD11blow/2 DCs does not abrogate
priming of T effector cells after subcutaneous immunization, why
then does this priming defect occur in Csf2rb2/2 mice? One
possibility is that other DC subsets besides dermal CD11blow/2
DCs can prime CD4 T cells [35], but that the ability of these other
DCs to prime requires that they receive a GM-CSF signal. Indeed,
GM-CSF is essential for IL-6 and IL-23 production by DCs during
the priming phase of autoimmune myocarditis [4] and is required
for inflammatory DC development from monocytes in a model of
repeated immunization with methylated BSA and CFA [36]. T
cells do not express GM-CSF receptor, so an intrinsic T cell defect
seems unlikely. While the source of GM-CSF after subcutaneaous
immunization is still unclear, antigen-specific T cells can produce
GM-CSF [5–7] and may augment responses by DCs during initial
priming of T effector cells.

T cell priming and ELISPOT assays
Mice were immunized subcutaneously in the hind footpads with
10 nanomoles MOG35–55 peptide (Sigma Genosys) emulsified in
complete Freund’s adjuvant (CFA) (BD Difco). Popliteal lymph
nodes were collected at day 7, and single cell suspensions were
used in ELISPOT assays with the IFNc ELISPOT antibody pair
from BD Biosciences on Multiscreen Filter Plates from Millipore.
An IL-17 ELISPOT was designed using anti-IL17A capture (clone
TC11-18H10) and detection (clone TC11-8H4.1) antibodies (BD
Biosciences). Cells were plated at 16106 cells/well, in duplicate,
and stimulated with either no antigen, or 10 micromolar
MOG35–55 peptide. Plates were developed after 16 hours of
stimulation at 37uC, and spots were counted on an Immunospot
counter (Cellular Technology Ltd.).

Antibodies
The following antibodies were purchased from BD Biosciences:
PE-Cy7 anti-CD11b (M1/70), PerCP-Cy5.5 anti-CD8a (53-6.7),
V500 anti-CD8a (53-6.7), PE anti-CD45RA (14.8), biotin antiCD24 (30F1), FITC CD24 (M1/69), APC anti-CD172a/SIRPa
(P84). FITC anti-CD11b (M1/70), APC eFluor 780-anti-CD11c
(N418), PE anti-CD103 (2E7), biotin anti-CD103 (2E7), eFluor450
anti-CD317/BST2 (eBio927), eFluor450 anti-MHCII (I-A/I-E)
(M5/114.15.2), APC anti-CD45.2 (104), and streptavidineFluor450 were purchased from eBioscience. PE anti-CD205/
DEC205 (NLDC-145) and APC anti-CD205/DEC205 (NLDC145) were purchased from Miltenyi. Alexa Fluor 488 anti-CD207/
Langerin (929F3.01) was purchased from Imgenex. PE antiCD326/EpCAM (G8.8) was purchased from Biolegend.

Flow cytometry
Inguinal lymph nodes and spleens were minced and digested in
5 ml Iscove’s modified Dulbecco’s media +10% FCS (cIMDM)
with 250 mg/ml collagenase B (Roche) and 30 U/ml DNase I
(Sigma-Aldrich) for 1 h at 37uC with stirring. Lungs and kidneys
were perfused with 10 ml DPBS via injection into the right
ventricle after transection of the lower aorta. Dissected lungs and
kidneys were minced and digested in 5 ml of cIMDM with 4 mg/
ml collagenase D (Roche) for 1 h at 37uC with stirring. EDTA
(5 mM final concentration) was added to cell suspensions, and cells
were incubated on ice for 5 min. Cells were passed through an
80 mm strainer before red blood cells lysis with ACK lysis buffer.
Cells were counted on a Vi-CELL analyzer, and 2–56106 cells
were used per antibody staining reaction.
Staining was performed at 4uC in the presence of Fc Block (clone
2.4G2, BD Biosciences or BioXcell) in FACS buffer (DPBS+0.5%
BSA+2 mm EDTA+0.02% sodium azide). For experiments involving intracellular anti-Langerin staining, cells were surface antibody
stained prior to fixation in 4% formaldehyde (Thermo Scientific) for
15 minutes at room temperature. Cells were subsequently permeabilized (DPBS+0.1% BSA+0.5% saponin) for 5 min at 4uC and
stained in the same permeabilization buffer with anti-Langerin
antibody. Cells were washed twice in permeabilization buffer before
returning them to FACS buffer. Flow cytometry was performed on
a FACSCantoII (BD Biosciences), and data was analyzed with
FlowJo software (Tree Star, Inc.).

Materials and Methods
Ethics statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Studies Committee of
Washington University (#20090320).

Mice
Wild-type 129S6/SvEv and C57BL/6 mice were purchased
from Taconic. Batf32/2 mice on a 129S6/SvEv background were
previously generated in our laboratory [27], and were backcrossed
for 10 generations to the C57BL/6 background. Csf2rb2/2 mice
on the C57BL/6 background were purchased from Jackson
Laboratory. Experiments were performed with sex-matched mice
at 8–20 weeks of age. Mice were bred and maintained in our
specific pathogen-free animal facility according to institutional
guidelines.

Induction of EAE
EAE was induced as previously described [14]. Briefly, mice
were immunized subcutaneously with 100 micrograms MOG35–55
peptide (Sigma Genosys) emulsified in complete Freund’s adjuvant
(CFA) (made with 5 mg/ml heat-killed Mycobacterium tuberculosis
H37Ra (BD Difco) in incomplete Freund’s adjuvant (BD Difco)).
Pertussis toxin (List Biological Laboratories) was injected intraperitoneally (300 ng) on days zero and two. Mice were observed
PLoS ONE | www.plosone.org

Bone marrow cultures
Bone marrow cells from femurs and tibias were collected and
red blood cells were lysed in ACK lysis buffer. Cells were cultured
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in four ml cIMDM in six-well plates at 26106 cells/ml containing
160 ng/ml murine Flt3L (Peprotech). At day seven of culture,
murine GM-CSF (Peprotech) was added to some wells at 20 ng/
ml. Non-adherent cells were collected at day nine for flow
cytometry.

the (C) C57BL/6 and (D) 129S6/SvEv backgrounds. Plots are
gated on CD11c+I-Ab+ cDCs. Numbers represent the percentage
of cells within the indicated gates. Data are representative of at
least six mice per genotype and background obtained in several
experiments. (E) FACS analysis of SDLN (inguinal) DCs from
C57BL/6, Batf32/2 (C57BL/6 background), and Csf2rb2/2 mice.
Left plots are gated on CD11chigh cells. Right plots are gated on
DEC205+CD8a+ cDCs. Numbers represent the percentage of cells
within the indicated gates. Data are representative of eight to ten
individual inguinal lymph nodes from four to five mice per
genotype obtained in two experiments. Data is depicted in these
plots are derived from analysis of the same mice used in Figure 2A,
but gated to analyze CD103 expression on DEC205+CD8a+
cDCs.
(TIF)

Supporting Information
Figure S1 Flow cytometric analyses of DCs in Batf32/2

mice. (A) FACS analysis of SDLN (inguinal) DCs from Batf3+/+
and Batf32/2 mice on both the C57BL/6 and 129S6/SvEv
backgrounds. Left plots from mice of each background are gated
on CD11c+BST22 cDCs. Right plots from mice of each
background are gated on migratory (DEC205+CD8a2) DCs.
Numbers represent the percentage of cells within the indicated
gates. Data are representative of at least six mice per genotype and
background obtained in several independent experiments. (B)
Absolute cell numbers of DEC205+CD8a+ DCs per individual
inguinal lymph nodes from C57BL/6 and Batf32/2 mice
(C57BL/6 background) calculated from the FACS analysis
performed in Figure 2A. Horizontal bars represent the geometric
mean, p value by unpaired student’s t test. (C) and (D) FACS
analysis of splenic DCs from Batf3+/+ and Batf32/2 mice on both
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